2021
Establishing Thresholds for Minimal Clinically Important Differences for the Peripheral Artery Disease Questionnaire
Peri-Okonny PA, Wang J, Gosch KL, Patel MR, Shishehbor MH, Safley DL, Abbott JD, Aronow HD, Mena-Hurtado C, Jelani QU, Tang Y, Bunte M, Labrosciano C, Beltrame JF, Spertus JA, Smolderen KG. Establishing Thresholds for Minimal Clinically Important Differences for the Peripheral Artery Disease Questionnaire. Circulation Cardiovascular Quality And Outcomes 2021, 14: e007232. PMID: 33947205, PMCID: PMC8254614, DOI: 10.1161/circoutcomes.120.007232.Peer-Reviewed Original ResearchConceptsPAQ summary scorePeripheral Artery QuestionnaireGlobal assessmentPatient's perspectiveSummary scoresDisease-specific health status instrumentHealth status assessment toolMinimal Clinically Important DifferencePAQ scoresPatient-reported outcomesRoutine clinical careHealth status instrumentsClinically Important DifferenceMultivariable linear regressionPORTRAIT registryDisease QuestionnaireMultivariable adjustmentVascular clinicMean ageUS cohortClinical trialsClinical careMCIDMCID estimatesMean difference
2020
Cilostazol and peripheral artery disease-specific health status in ambulatory patients with symptomatic PAD
Mohammed M, Gosch K, Safley D, Jelani QU, Aronow HD, Mena C, Shishehbor MH, Spertus JA, Abbott JD, Smolderen KG. Cilostazol and peripheral artery disease-specific health status in ambulatory patients with symptomatic PAD. International Journal Of Cardiology 2020, 316: 222-228. PMID: 32464249, DOI: 10.1016/j.ijcard.2020.05.042.Peer-Reviewed Original ResearchConceptsPeripheral Artery QuestionnaireHealth statusDisease-specific health statusPatient-reported health statusHeart failure historyNon-cilostazol groupUse of cilostazolPAQ scoresImprovement of symptomsSubsequent health statusQuality of lifeCilostazol therapyCilostazol useSymptomatic PADPatient characteristicsPharmacological optionsAmbulatory patientsLimitation scoresMean ageFunctional statusUS cohortTreatment goalsSummary scoresCilostazolPatients